Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BA3071 · 1 trial · 2 indications
Phase 1: Safety Profile
Phase 1: Safety Profile
Phase 1 and 2: Safety Profile
Phase 2: Efficacy
| Arm | Type | Description |
|---|---|---|
| BA3071 | EXPERIMENTAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 |
| Combination Therapy | EXPERIMENTAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor |
| Combination Therapy + Chemotherapy | EXPERIMENTAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor + Chemotherapy |
| Neoadjuvant Combination Therapy + Chemotherapy | EXPERIMENTAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor + Chemotherapy prior to surgical resection |
| Name | Type | Description |
|---|---|---|
| BA3071 | BIOLOGICAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 |
| Nivolumab | BIOLOGICAL | Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1 |
| Pembrolizumab | BIOLOGICAL | Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor |
| Pemetrexed (Alimta) | DRUG | pemetrexed with either cisplatin or carboplatin |
Inclusion Criteria: * Patients must have measurable disease. * Age ≥ 18 years * CLTA-4 blocking-antibody naïve * Adequate renal function * Adequate liver function * Adequate hematological function * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Patients must have...
BA3071 is an investigational monoclonal antibody being developed for the treatment of non-small cell lung cancer (NSCLC). It is currently being studied in a Phase 1/2 clinical trial in patients with solid tumors, including NSCLC and melanoma.
BA3071 targets CTLA-4, a protein that plays a role in regulating immune responses. By targeting CTLA-4, BA3071 is designed to modulate the immune system's ability to fight cancer cells.
BA3071 is being developed by BioAtla, Inc., a biopharmaceutical company. BioAtla is publicly traded on the Nasdaq under the ticker symbol BCAB.
BA3071 is currently in Phase 1 clinical development. It is being evaluated in a Phase 1/2 study, but the drug is still in the early stages of clinical testing and is not yet approved by regulatory authorities.
BA3071 is being studied in a Phase 1/2 clinical trial with the identifier NCT05180799. This trial is titled 'A Phase 1/2 Study of BA3071 in Patients With Solid Tumors' and is currently active but not recruiting participants.
No alternative names for BA3071 have been reported. It is a unique investigational drug candidate developed by BioAtla, Inc. and is not known to be identical to any other approved or investigational therapy.